/>

Pages

Sunday, September 15, 2019

Weekly summary: 9 Sep. - 13 Sep. 2019

 

NEWS FROM USA

505(b)(2) APPROVAL

Approval Date

Product Name

NDA Sponsor

Comment

10 Sep 2019

Glucagon Injectable – Prefilled syringes and autoinjector

(Gvoke)

Xeris Pharma

Gvoke is the first ready-to-use Glucacgon injectable formulation approved in the US.

Currently available two other emergency Glucagon products (From Lilly and Novo Nordisk) are lyophilized formulations that require reconstitution with diluent.

Another Glucagon product from Fresenius is also lyophilized powder. Fresenius’ Glucagon was marketed only as diagnostic aid. Recently on 9th September, Fresenius received approval to market its Glucagon product for the treatment of hypoglycaemia.

Comparison between Glucagon by Lilly, Novo Nordisk and Xeris is available here.

Xeris Pharma Press release

Prescribing InformationFDA Approval letter

 

NEW GENERICS LAUNCHES IN US

LAUNCH DATE

DRUG

Marketer

Corresponding RLD

Annual sales quoted in press release as per IQVIA 

Press Release

11 Sep 2019

Fosaprepitant injection

Dr Reddy

Emend

(Merck)

$279 Million

Link

09 Sep 2019

Phenylephrine Injections

(5 ml and 10 ml)

Hikma Pharma

N/A

$28 Million

Link

05 Sep 2019

Fosaprepitant injection

Apotex

Emend

(Merck)

$279 Million

Link

05 Sep 2019

Bupropion Hydrochloride ER Tablets

Dr Reddy

Zyban

(GSK)

$5.4 Million

Link

 

NEW EXCLUSIVITY LISTINGS IN THE ORANGE BOOK

New PC (Patent Challenge) exclusivity listing in the orange book

Drug

Applicant

Corresponding RLD

PC exclusivity expiration date

Nicotine Polacrilex oral lozenges

PLD acquisitions

Nicorette (Glaxo)

1 Oct. 2019

                         

New CGT (competitive generic therapy) exclusivity listing in the orange book

Drug

Applicant

Corresponding RLD

CGT exclusivity expiration date

Aminocaproic acid oral syrup

Amneal

Amicar (Clover)

26 Feb. 2020

 

Complete List of products with granted CGT exclusivity till date is available here.

NEW STRENGTH APPROVALS

Write us on pharmacaption@gmail.com, if you want to know new strengths approved in existing NDAs during August 2019.

OTHER NEWS FROM US

FDA issued alert statement on NDMA (probable carcinogen) found in the samples of Ranitidine - Link

 

If you have any query/suggestion then please write us at pharmacaption@gmail.com

No comments:

Post a Comment